Dr Andrew Brockway
Chief Executive Officer
→ Register Your Interest
English
Dr Rathjen is the Chair of the Board of Doherty Clinical Trials Ltd. She is also the Chief Executive Officer of Carina Biotech, a clinical stage CAR-T biotechnology company.
Dr Rathjen is a highly experienced and respected leader in the biotechnology and pharmaceutical industries within Australia and internationally, and has achieved in excess of $800 million in deals including partnerships with Merck & Co., J&J, Abbott (AbbVie), Celgene, Nycomed (Takeda) and Merck KGaA. An immunologist by training, Dr Rathjen has extensive R&D experience in the areas of infection and immunity, inflammation, oncology and neuroscience, covering multiple treatment modalities.
Additionally, Dr Rathjen is currently Executive Chair of US-headquartered Bioasis Technologies Inc. She is also a member of the Australian Medical Research Future Fund Advisory Board, the Million Minds Mental Health Research Mission Expert Panel, the Stem Cell Therapies Mission Expert Panel and the Federal Government’s Biomedical Translation Fund Committee.
A skills-based board combines comprehensive experience in academic research, financial strategy, commercial development and biotechnology & pharmaceutical industries. Along with the specialised leadership team, this expertise drives Doherty Clinical Trials Ltd unique capabilities.
Chief Executive Officer
Chief Medical Officer
Senior Program Manager
.png)
Clinical Operations and Nursing Director
Quality and Compliance Director
Human Infection Challenge Trial Consultant
Director
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}